NovaBridge Subsidiary Visara Assigns VIS-101 License to Everest Medicines for Asian Markets
核心洞察
NovaBridge subsidiary Visara (搜索) has assigned its exclusive license for VIS-101 (搜索), a novel bifunctional biologic targeting VEGF-A (搜索) and ANG-2 (搜索), to Everest Medicines (搜索) for development in Greater China and certain Asian countries.
VIS-101 (搜索) is designed to provide more effective and durable treatment than current standard of care for wet age-related macular degeneration (搜索), diabetic macular edema (搜索), and retinal vein occlusion (搜索).
The drug is currently completing a Phase 2 study in China and is expected to be Phase 3-ready in 2026.
NovaBridge Biosciences (搜索) announced that its subsidiary Visara (搜索) has assigned its exclusive license agreement to Everest Medicines (搜索) for the development, manufacture and commercialization of VIS-101 (搜索) in Greater China, Singapore, South Korea, and certain Southeast Asian countries. The strategic partnership aims to accelerate development of the novel bifunctional biologic for ophthalmic indications.
Novel Dual-Target Approach for Eye Diseases
VIS-101 (搜索) represents a second-in-class, potentially best-in-class bifunctional biologic that simultaneously targets VEGF-A (搜索) and ANG-2 (搜索) pathways. The drug is designed to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (搜索) (wet AMD), diabetic macular edema (搜索) (DME), and retinal vein occlusion (搜索) (RVO) compared to current standard of care therapies.
"With its unique potency and potential to provide more durable treatment benefits, we believe VIS-101 (搜索) has a robust opportunity to be a second-in-class with best-in-class potential treatment for patients around the world with wet AMD, DME and RVO," said Emmett T. Cunningham, Jr. MD, PhD, MPH, Co-Founder and Executive Chairman of Visara (搜索).
Clinical Development Progress
VIS-101 (搜索) has completed initial safety and dose-escalation studies in both the United States and China. The drug is currently completing a large, randomized, dose-ranging Phase 2 study in China for wet AMD. According to the companies, VIS-101 is anticipated to be Phase 3-ready in 2026.
The partnership leverages Everest Medicines (搜索)' established clinical development and commercialization capabilities in Asian markets. "Everest Medicines' clinical and commercial expertise could enable us to accelerate the development and bring VIS-101 (搜索) to patients across Asia sooner," Cunningham noted.
Strategic Partnership Structure
Under the assignment agreement, Everest Medicines (搜索) will assume all payment obligations under the assigned license agreement and reimburse Visara (搜索) for any upfront payments already made. The partnership covers Greater China, Singapore, South Korea, and certain Southeast Asian countries, while Visara retains global rights outside these territories.
"Partnering with Visara (搜索) brings a highly differentiated and commercially attractive asset to Everest's late-stage pipeline and paves the way for our entry into the ophthalmology market, an area of significant unmet need," said Ian Woo, President and Chief Financial Officer of Everest Medicines (搜索).
Board Appointment Strengthens Leadership
NovaBridge has appointed Ian Woo to its Board of Directors, bringing substantial expertise in international biopharma finance, operations and management. Woo's background includes serving as a managing director in the global healthcare group of Lazard Frères & Co. LLC, where he helped raise over $1 billion in equity financings and advised on merger and acquisition transactions aggregating more than $35 billion in value.
"Ian's extensive track record in strategic transactions, operations and management will be a valuable asset to NovaBridge as we work to accelerate the global development of transformative medicines and create value for patients and investors," said Sean Fu, PhD, Chief Executive Officer of NovaBridge.
Company Background
Visara (搜索) is a clinical-stage biopharmaceutical company focusing on the development of best-in-class ophthalmic therapeutics, led by internationally recognized specialist in infectious and inflammatory eye disease Emmett T. Cunningham, Jr. NovaBridge is the majority shareholder of Visara and maintains control of global rights to VIS-101 (搜索) outside of Greater China and certain Asian countries.
The licensing agreement represents NovaBridge's strategy of collaborating with global innovators to accelerate development of novel medicines. "This Agreement with Everest Medicines (搜索) is an excellent fit with NovaBridge's focus on collaborating with global innovators to accelerate the development of novel medicines such as VIS-101 (搜索)," Fu stated.